Routes reported in the literature include intraperitoneal, subcutaneous, intramuscular, intravenous, and oral administration
New drugs with different mechanisms of action may be more efficacious in some patient populations, with different adverse event profiles
For providers, offering financing options may also support higher treatment acceptance and better continuity of care, particularly for multistep procedures or long-term care pathways
Yet overlapping analyses of variable quality complicate drawing definitive, comprehensive conclusions
Available from: James McCormack MP-RbRR, MD and Barbara Roberts, MD
Dysbiosis, or microbial imbalance, is believed to disrupt this axis, leading to alterations in gut motility, pain sensitivity, and immune responses, which are common in conditions like IBS and IBD